We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Niox Group Plc | LSE:NIOX | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.80 | 1.27% | 63.60 | 468,588 | 16:35:29 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 62.40 | 64.00 | 64.00 | 62.60 | 62.60 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 36.8M | 9.5M | 0.0224 | 28.57 | 266.35M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:29 | UT | 13,669 | 63.60 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 05/12/2024 | 17:40 | UK RNS | Niox Group PLC Holding(s) in Company |
| 11/11/2024 | 17:05 | UK RNS | Niox Group PLC Holding(s) in Company |
| 28/10/2024 | 17:12 | UK RNS | Niox Group PLC PCA Dealing |
| 25/10/2024 | 16:08 | UK RNS | Niox Group PLC Director/PDMR Shareholding, RPT Update & TVR |
| 25/10/2024 | 12:58 | UK RNS | Niox Group PLC Holding(s) in Company |
| 17/10/2024 | 06:00 | UK RNS | Niox Group PLC Result of Tender, Related Party Transaction & TVR |
| 16/10/2024 | 10:45 | UK RNS | Niox Group PLC Result of General Meeting |
| 01/10/2024 | 06:00 | UK RNS | Niox Group PLC Total Voting Rights Update |
| 30/9/2024 | 12:00 | UK RNS | Niox Group PLC Block Listing Interim Review |
| 24/9/2024 | 20:29 | ALNC |  EARNINGS: HSS Hire swings to loss, while Niox profit increases |
Niox (NIOX) Share Charts1 Year Niox Chart |
|
1 Month Niox Chart |
Intraday Niox Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 02/12/2024 | 19:40 | NIOX GROUP - expertise in asthma diagnosis and management | 242 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 14/12/2024 08:20 by Niox Daily Update Niox Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NIOX. The last closing price for Niox was 62.80p.Niox currently has 424,127,241 shares in issue. The market capitalisation of Niox is £271,441,434. Niox has a price to earnings ratio (PE ratio) of 28.57. This morning NIOX shares opened at 62.60p |
Posted at 02/12/2024 19:09 by edwardt Surely that is not good for niox! |
Posted at 08/11/2024 15:27 by earwacks Amazing 1 automatic share trade @63.2 drops the price several hundred thousand, but no amount of buys of 250,000 moves the Sp a jot |
Posted at 23/10/2024 10:45 by earwacks Clearly there has been some selling yesterday but quite a few buying back in presumably re-investing winnings. I fully intend to do the same. Just a question of timing. We won’t get another TU update till late January. A lot depends on what mr Griffiths and co do. I think there will be plenty of appetite even if they do offload a few more. Singer have reinstated their buy recommendation even though not increasing revenue upgrade but they have increased the EBITDA ad raised share price target siting further payouts as they accumulate cash again. 5 brokers have targets in a range of 69-91p. The good thing is some kind of dividend or payout is pretty certain plus we don’t yet know how the new upgraded version will sell. They are going to push sales and hoping to grow substantially in the USA. Then there will hopefully be further updates on home test developments. I’m not entirely convinced by Mills suggesting most of the money has been made here. It has more than doubled from its low, but I can see a buyout price in excess of £1.00 per share, although unfortunately probably not Astra (they could buy this with a days revenue possibly). Wallet investor have a 5 year target of £2.67!Maybe many stocks can outstrip that. In the meantime it is definitely a core holding and nice little earner with a 5 percent annual return. GL |
Posted at 17/10/2024 06:40 by earwacks Payment by October 22. Slight over application to the tender by around 4 million shares. I would imagine mostly fund managers. Looks like everyone took part in tender including directors and major shareholders. Now will we see a rush to exit. May provide an excellent opportunity to top up. I suppose as Astra Zenica took part maybe rules them out for possible takeover. I think their holding is mostly a hangover from the Circassia debacle.Mugs game trying to predict! Ultimately this looks a great company now and for the future. Much appreciate the buyback at a premium |
Posted at 08/10/2024 15:06 by earwacks O good Jimmy. I see the cut off date is actually oct 15th. I think most people have the same plan to reinvest at a lower price. Be interesting to see how that works out. I will probably keep the cash for a bit to see how the share price settles. Don’t think It needs to be rushed reinvesting as the home test is still a way off production, but a possible takeout is always on the cards. In the meantime we keep getting a hefty wedge of the increasing cash generation |
Posted at 21/7/2024 18:37 by badday Gets a mention on the Paul Scott podcast ( always worth a listen)Interesting that he says Christopher Mills due to do Paul Hills (Vox Markets) interview next week. Christopher Mills was thinking it was fully valued for now, but growing into that value. Might have something to say Anyway Paul Scott comments below: “Another interesting company that I've gone green on, which might surprise you, because it's not my usual sort of value share, is a thing called NIOX, N-I-O-X. That put a trading update out. I had another refresh of the figures. It's quite pricey, but it does something to do with asthma products. And look at the shareholder list on that. You've got Harwood, you've got AstraZeneca, and you've got somebody else who owned about a third of the shares, who were all big name major investors. So the way I look at it is, they've done the due diligence for us, haven't they? And they obviously think it's good, although... Oh, that was it, Rathbones had bought some shares from the other two big shareholders. Richard Griffith, I think, was the other one who's got a big position there. He doesn't get everything right, nobody does, but he's certainly a smart cookie. Anyway, so Niox, I think, is worth you having a look at.” From Small Caps Podcast with Paul Scott: Episode 29 (20 July 2024) - UK Small/Mid Caps with Paul Scott, 20 Jul 2024 This material may be protected by copyright. |
Posted at 14/6/2024 11:11 by saadia110 Think he is still selling. 1.3M buy just gone in at 68.3p. Even with a big seller there are an almost equal number of buyers so don't expect the share price to dip too much. |
Posted at 27/4/2024 14:19 by earwacks Astra dissolved their partnership with Circassia over Tudorza and Duklar inhaler for COPD.Astra retained commercial rights in consideration of 150 million dollar debt and retained 18 percent of Circassia, now Niox. Astra have since offloaded this product. Not sure how successful it has been. Probably nothing like the FeNo tester. What Niox have is the development of the best Asthma diagnostic device and 600 million tax credit for the Circassia debacle. Meaning they will never pay tax on their very cash generative device. The tax credit is also transferable which makes it an added asset to their £270 million market cap. The directors are probably nearing retirement. They have built a highly profitable business from the wreckage of Circassia, making it a market leader in its field, but still only tapping 5 percent of possible world market. Added to that they are developing a domestic kit, which if successful will probably appeal to a us pharma giant, not necessarily just Astra, who as you say may not be interested as it is Gsk that have recently purchased a company that have developed an asthma drug. Potential for Niox is pretty big and are at an interesting stage where they might need some serious gearing up to reach potential global markets, whilst having converted themselves into a growing cash machine. Although expensive on last years results I don’t think forecasters have quite got their head around the potential of Niox yet |
Posted at 23/2/2024 18:18 by earwacks I think it’s held up well considering The uk is the worst performing market in the world and many British companies make most of their money in global business.This is a recent high for NIOX. It is similar to share price movement last year between update and actual results. News on dividend and cash position should help re establish the share price Then of course there is the expectant takeover by AZN Why else would they hold 16 percent of the. Company? Gl all |
Posted at 19/12/2023 06:03 by earwacks Paul Hill catches up with GuyHarwood on his various funds. Brief mention of Niox and the home kit. Suggests they would need a partner to get this to retail. Well we know for a fact they have set aside money ( 2 million) for the home kit, and aside from that it sounds like the accelerating cash generation is set to continue with solid dividend cover. I listen with great interest to his other life science projects which all seem to need funding in some way at a very difficult time.They have no tax to pay for yonks due to the unbelievable tax loss carry over of 600 million! So what are they going to do with the ever expanding cash pile? Richard Griffiths still reducing gradually and still the largest holder. Clearly someone is happy to take them off his hands but maybe what has halted the rise of the share price for now. With the share price seemingly consolidating around this level looks a good opportunity to add. As keen as I am to diversify, I just can’t see a better case for investing than here. I particularly like that they don’t really push this stock. They don’t need to, the numbers do the talking! Still up for a buy out but the sales will quickly catch up the premium rating PE of 22, not actually that expensive for a company with high teens revenue growth and great margins with recurring refill product. Gl |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
